Adenocarcinoma Prostate With Neuroendocrine Differentiation
Authors:
- Sarthak TripathySTSarthak Tripathy
- Shreya Datta GuptaSGShreya Datta Gupta
- Abhinav SinghalASAbhinav Singhal
- Rakesh KumarRKRakesh Kumar
- Chandrasekhar BalCBChandrasekhar Bal
- Shamim Ahmed ShamimSSShamim Ahmed Shamim
- 1 April 2018
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (4) , 248-249
Abstract
68Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of 68Ga-PSMA PET/CT imaging and benefit of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in such cases.Keywords
This publication has 9 references indexed in Scilit:
- Molecular Imaging in Neuroendocrine Differentiation of Prostate CancerClinical Nuclear Medicine, 2017
- 68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine DifferentiationClinical Nuclear Medicine, 2016
- Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine?Frontiers in Oncology, 2015
- The Many Faces of Neuroendocrine Differentiation in Prostate Cancer ProgressionFrontiers in Oncology, 2014
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostateWorld Journal of Surgical Oncology, 2008
- Molecular Positron Emission Tomography and PET/CT Imaging in Urological MalignanciesEuropean Urology, 2007
- Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical ProstatectomyEuropean Urology, 1999
- Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled DeoxyglucoseJournal of Urology, 1996